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Recently,	neuroprotective	and	anti­inflammatory	effects	of	an	extract	of	Scrophularia striata 
Boiss	(Sc. st.)	(Scrophulariaceae)	were	shown	in	rodents.	In	our	study,	we	investigated	the	
effects	of	the	Sc. st. extract	on	anxiety	and	depression­like	behaviors	in	rats	and	tried	to	find	
possible	mechanisms	 responsible	 for	 these	 influences.	The	 elevated	 plus­maze	 (EPM)	 and	
forced	swimming	test	(FST)	were	used.	The	ethanol	extract	of	Sc. st.	was	perorally	adminis­
tered	at	different	doses	(20,	50,	100,	160,	and	220	mg/kg).	We	also	assessed	interaction	be­
tween	the	effective	doses	of	Sc. st.	and	GABAA	receptors	in	the	brain.	It	was	found	that	Sc. st. 
at	doses	of	100	and	160	mg/kg	increased	normalized	values	of	the	open	arm	time	and	number	
of	entries	in	the	EPM	and	decreased	the	immobility	time	in	the	FST	in	comparison	with	the	
control	 group,	 indicating	 anxiolytic	 and	 antidepression	 effects,	 respectively.	 Intracerebro­
ventricular	administrations	of	a	GABAA	receptor	agonist,	muscimol	(0.5,	0.75,	and	1	µg/rat),	
enhanced the	respective	Sc. st. effects,	while	a	GABAA	receptor	antagonist,	bicuculline	(0.5,	
1	and	2	µg/rat),	blocked	these	effects.	Thus,	anxiolytic	and	antidepressive	effects	of	the	active	
components	of	Sc. st.	may	be	mediated	by	modulation	of	the	GABAergic	system.	
Keywords: Scrophularia striata, anxiety, depression, elevated plus-maze, forced 
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INTRODUCTION
Neuropsychiatric	 disorders,	 like	 anxiety	 and	 depres­
sion,	 are	 common	 causes	 of	 a	 reduced	 quality	 of	
life	 and,	 especially,	 of	 impaired	 functioning	 in	 aged	
subjects	 [1].	 Recent	 studies	 showed	 that	 increased	
levels	and	severity	of	anxiety	and	depression	in	humans	
and	 animals	 can	 be	 associated	 with	 inflammatory	
processes	in	the	brain	[2,	3].	
It	 is	 well	 known	 that	 various	 neurotransmitter	
systems,	 in	 particular	 serotonergic,	 GABA­ergic,	
dopaminergic,	and	glutamatergic	ones,	are	significantly	
involved	 in	 the	 regulation	and	modulation	of	anxiety	
and	depression­like	behaviors	at	molecular	levels	of	the	
brain	 structures	 [4­7].	Moreover,	 recent	 studies	 have	
provided	 substantial	 evidence	 that	 pharmacoactive	
components	of	certain	herbal	medicines	can	effectively	
modulate	 the	 state	 of	 different	 neurotransmitter	
systems	in	rodents	[8].	
GABA	is	an	amino	acid	that	acts	as	the	main	inhibitory	
neurotransmitter	in	the	CNS	through	different	receptor	
sites,	 classified	 as	 GABAA,	 GABAB,	 and	 GABAC 
receptors	[9].	The	involvement	of	GABAA	receptors	in	
the	regulation	of	anxiety	and	depression	has	been	the	
subject	 of	 extensive	 laboratory	 and	 clinical	 studies.	
It	 is	 well	 known	 that	 GABA­ergic	 agents	 and	 drugs	
demonstrate	 strong	 anxiolytic	 and	 antidepressive	
effects	 in	 humans	 and	 animals.	 Results	 of	 a	 number	
of	clinical	studies	allowed	researchers	to	believe	that	
GABAA	 receptor	protein	 is	 the	main	molecular	 target	
for	anxiolytic	drugs	and	antidepressants	in	anxiety	and	
depression	disorders	[9].	
Previous	 experimental	 studies	 have	 shown	
that	 an	 extract	 from	 Scrophularia striata	 Boiss	
(Scrophulariacea, figword; hereafter, Sc. st.)	possesses	
significant	 neuroprotective	 and	 anti­inflammatory	
effects	 [10,	 11].	 A	 quercetin	 flavonoid	 was	 isolated	
from	 Sc. st. compounds	 by	 Monsef–Esfahani	 and	
colleagues	 [12].	 Several	 studies	 demonstrated	 that	
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this	 flavonoid	exerts	neuroprotective,	 anxiolytic,	 and	
antidepressive	effects	on	laboratory	animals	[13­15].	
In	our	study,	we	tried	to	evaluate	the	effects	of	the	
Sc. st.	 extract	and	possible	mechanisms	of	 the	 	action	
of	 this	 drug	 in	 the	 elevated	 plus­maze	 and	 forced	
swimming	tests	(EPM and	FST,	respectively)	in	rats.	
METHODS 
Animals. Male	 Wistar	 rats	 (body	 mass	 240­280	 g)	
were	purchased	from	the	Pasteur	Institute	of	Iran.	The	
animals	were	individually	housed	in	standard	rat	cages.	
The	 colony	 room	 was	 maintained	 under	 a	 12/12­h	 
light/dark	 cycle	 (light	 on	 at	 07.00)	 at	 23	 ±	 1°C and 
50	 ±	 5%	 humidity.	Animals	 were	 allowed	 unlimited	
access	to	food	and	water,	except	during	the	behavioral	
tests.	All	experiments	were	performed	between	12.00	
and	 17.00	 h,	 and	 each	 rat	 was	 tested	 only	 once.	All	
stages	 of	 the	 study	 were	 performed	 using	 protocols	
approved	 by	 the	 Research	 and	 Ethics	 Committee	 of	
the	 Tabriz	 University	 of	Medical	 Sciences	 and	 were	
conducted	 under	 the	 recommended	 conditions	 of	 the	
Guide	for	the	Care	and	Use	of	Laboratory	Animals	of	
the	National	Institute	of	Health	(NIH;	Publication	No.	
85­23,	revised	1985).	Eight	animals	were	used	in	each	
group	 of	 the	 experiments.	 All	 efforts	 were	 made	 to	
minimize	animal	suffering	or	discomfort	and	to	reduce	
the	number	of	animals	used.	
Plant Collection, Preparation of the Extract, and 
Its Administration. The	 aerial	 parts	 of	 Sc. st.	 were	
collected	 in	 January,	 2011	 in	 a	 Northwestern	 part	
of	 Iran	 (in	 the	 Ilam	 region)	 and	 dried	 at	 30	 ±	 1°C.	
A	 sample	 was	 authenticated	 by	 M.	 Kosari­Nasab,	
and	there	was	a	voucher	specimen	of	this	plant	at	the	
Herbarium	 of	 the	 Tehran	 University	 (No.	 36501).	A	
total	 extract	 from	 Sc. st.	 was	 obtained	 as	 previously	
described	[10].	The	extract	was	dissolved	in	water	and	
used	at	appropriate	concentrations.	Different	groups	of	
rats	received	peroral	administrations	of	various	doses	
of the Sc. st.	extract	(20,	50,	100,	160,	or	220	mg/kg)	
or	vehicle	(equal	volumes)	consecutively	for	12	days.	
The	test	sessions	were	performed	60	min	after	the	last	
treatment.	
Intracerebroventricular (i.c.v.) Injections of the 
Drugs Influencing GABA-ergic Effects. Muscimol	
and	 bicuculline	 (Sigma,	 USA)	 were	 used	 for	 i.c.v.	
injections	in	the	experiments.	Muscimol	was	dissolved	
in	sterile	0.9%	saline,	while	bicuculline	was	dissolved	
in a minimal volume of diluted acetic acid and then 
diluted	 to	 the	 required	 volume	with	 vehicle.	 Control	
animals	 received	 saline	 or	 vehicle.	 Drug	 solutions	
were	freshly	prepared	before	administration.
Animals	 were	 allowed	 to	 adapt	 to	 the	 laboratory	
conditions	 for	 at	 least	 one	 week	 before	 surgery.	
They	were	 i.p.	 anesthetized	with	 50	mg/kg	 ketamine	
hydrochloride	+	4	mg/kg	xylazine	(Alfasan,	Woerden,	
Holland)	 and	 placed	 in	 a	 stereotaxic	 instrument.	
Stainless	 steel	 guide	 cannulas	 (21­gauge)	 were	
stereotaxically	 implanted	 according	 to	 the	 following	
coordinates:	 AP	 –0.82	 mm,	 ML	 +1.5	 mm,	 and	 DV	
+2.0	mm	related	to	the	bregma	[16].	The	cannula	was	
fixed	 to	 the	 skull	 with	 acrylic	 cement.	 The	 animals	
were	 then	 allowed	 7	 days	 before	 the	 test	 to	 recover	
from	surgery	and	were	handled	about	4	min	each	day	
prior	to	behavioral	testing	(to	minimize	a	nonspecific	
stress).	 The	 drugs	 mentioned	 above	 were	 injected	
with	 a	Hamilton	 syringe	 through	 an	 internal	 cannula	
(27­gauge)	 terminating	 1	 mm	 below	 the	 tip	 of	 the	
guide	 into	 the	 right	 lateral	 cerebral	 ventricle	 over	
a	 60­sec­long	 period.	 The	 inner	 cannula	 was	 left	 in	
place	 for	 additional	 60	 sec	 to	 allow	 diffusion	 of	 the	
solution	and	to	reduce	the	possibility	of	a	reflux.	The	
injections	were	made	5	min	before	testing	[17]
Different	 groups	 of	 rats	 received	 i.c.v.	
microinjections	 of	 the	 GABAA receptor	 agonist	
muscimol	(0.5,	0.75,	and	1.0	µg/rat).	The	other	groups	
were	 injected	 with	 the	 GABAA receptor	 antagonist	
bicuculline	(0.5,	1.0,	and	2.0	µg/rat).	These	rats	were	
compared	 with	 the	 vehicle	 control	 groups.	 The	 test	
session	was	performed	5	min	after	i.c.v.	injections.	
Elevated Plus-Maze (EPM) Test. The	 EPM	 was	
a	 plus­shaped	 apparatus	 constructed	 from	 wood	 and	
elevated	to	a	50	cm	height	above	the	floor.	The	apparatus	
with	an	open	roof	had	a	central	platform	(10	×	10	cm),	 
two	open	arms	(50	×	10	cm),	and	two	equalized	closed	
arms	(50	×	10	×	50	cm)	opposite	to	each		other.	Testing	
was	 performed	 in	 the	 center	 of	 a	 quiet	 and	 dimly	 lit	
room.	The	behavior	data	were	 collected	by	a	 “blind”	
observer	 using	 a	 mirror	 suspended	 above	 the	 EPM.	
Five	minutes	after	the	respective	i.c.v.	drug	treatment,	
rats	were	placed	individually	at	the	center	of	the	EPM,	
facing	 one	 of	 the	 open	 arms.	The	 observer	measured	
(i)	 time	 spent	 in	 the	open	 arms,	OAT,	 (ii)	 time	 spent	
in	 the	 closed	 arms,	CAT,	 (iii)	 number	 of	 entries	 into	
the	open	arms,	OAE,	 and	 (iv)	number	of	 entries	 into	
the	closed	arms,	CAE,	during	5­min­long	test	periods.	
An	 entry	was	 defined	 as	 all	 four	 paws	 of	 the	 animal	
inside	 the	 arm.	 The	 EPM	was	 cleaned	 with	 distilled	
water	 after	 each	 testing.	 The	 open­arm	 activity	 was	
quantified	 as	 an	OAT	value	 relative	 to	 the	 total	 time	
spent	 in	 any	 arm,	 and	 the	OAE	was	normalized	with	
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respect	to	the	total	number	of	entries	into	any	arm;	the	
data	obtained	were	expressed	as	percentage.	Total	arm	
entries	 (OAE	 +	 CAE)	 were	 used	 as	 an	 index	 of	 the	
intensity	of	locomotor	activity	(LMA)	[17,	18].
Forced Swimming Test (FST). Rats	 were	
individually	 placed	 into	 a	 transparent	 glass	 cylinder	
(height	80	cm,	diameter	30	cm)	filled	for	40	cm	with	
water	maintained	at	23	±	1°C.	The	water	was	changed	
after	each	test.	For	the	first	exposure,	rats	were	placed	
in	the	water	for	15	min	(pre­test	session).	Twenty­four	
hours	later,	animals	were	placed	in	the	water	cylinder	
again	 for	 a	 5	 min	 session	 (test	 session),	 and	 total	
duration	of	immobility	within	this	time	was	measured.	
Each	 rat	 was	 judged	 to	 be	 immobile	 when	 it	 ceased	
struggling	 and	 remained	 floating	 motionless	 in	 the	
water	and	making	only	movements	necessary	to	keep	
its	 head	 above	 the	 water.	A	 decrease	 in	 the	 duration	
of	 immobility	 has	 been	 qualified	 as	 an	 index	 of	 the	
antidepressant­like	effect	[19].
Verification of the Cannula Position. At the end 
of	 the	 behavioral	 tests,	 each	 rat	was	 euthanized	by	 a	
chloroform	overdose,	and	then	1	µl	of	a	1%	methylene	
blue	 solution	 was	 injected	 i.c.v.	 as	 a	 marker	 of	 the	
injection	site.	Brains	were	removed	after	decapitation	
and	 fixed	 in	 a	 10%	 formalin	 solution	 for	 at	 least	 10	
days.	The	brains	were	sliced,	and	the	sites	of	injection	
were	 verified	 according	 to	 the	 atlas	 [16].	 Data	 from	
animals	 with	 the	 injection	 sites	 located	 outside	 the	
ventricular	region	were	not	used	in	the	analysis.
Statistics. All	analyses	were	performed	using	IBM	
SPSS	Statistics,	version	20.	Since	 the	numerical	data	
displayed	 the	 normal	 distribution	 and	 homogeneity	
of	 the	 variance,	 one­way	 ANOVA	 was	 used	 for	
comparison	 between	 the	 effects	 of	 different	 doses	 of	
drugs	 and	 those	 of	 vehicle.	 Two­way	 ANOVA	 was	
used	 for	 evaluation	 of	 interactions	 between	 drugs.	
Following	 a	 significant	 F	 value,	 post hoc	 analysis	
(Tukey’s­test)	 was	 performed	 for	 assessing	 specific	
group	comparisons.	Differences	with	P	<	0.05	between	
experimental	 groups	 at	 each	 point	 were	 considered	
statistically	significant.	
RESULTS
Effects of the Sc. st. Extract on Anxiety-Related 
Behavior in the EPM Test. Figure	1	shows	the	effects	
of	oral	administration	of	different	doses	of	the	Sc. st. 
extract	or	vehicle	consecutively	for	12	days.	One­way	
ANOVA	and	post hoc	analysis	revealed	that	the	effects	
of Sc. st.	 were	 significant	 at	 the	 doses	 of	 100	 and	 
F i g. 1.	Effects	of	peroral	administration	of	different	doses	of	an	
extract	 from	Scrophularia striata	 or	 vehicle	 consecutively	 for	 12	
days	on	 rat	 behavior	 in	 the	 elevated	plus­maze	 test.	Doses	of	 the	
extract	 (20,	50,	100,	160,	and	220	mg/kg)	are	shown	below.	Bars	
represent	normalized	means	±	s.e.m.	(n	=	8)	of	open­arm	time,	%	
(A),	 open­arm	 entries,	 %	 (B),	 and	 indices	 of	 locomotor	 activity	
(C).	**P <	0.01	and	***P <	0.001,	compared	to	the	control	(Contr.)	
group.
Р и с. 1.	Впливи	перорального	введення	екстракту Scrophularia 
striata в	 різних	 дозах	 або	 розчинника	 (протягом	 12	 днів)	 на	
поведінку	щурів	у	піднятому	лабіринті. 
A%
%
40
40
30
30
20
20
10
10
0
0
14
12
10
8
6
4
2
0
Contr. 20 50 100 160 220 mg/kg
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160	 mg/kg.	 Administrations	 of	 Sc. st.	 increased	 the	
OAT	(F
(5,	42)
	=	4.17,	P <	0.005)	and	OAE	(F
(5,	42)
	=5.89,	 
P <	 0.001)	 but	 did	 not	 significantly	 change	 LMA	 
(F
(5,	42)
	=	0.65,	P >	0.05).	These	data	indicate	that	clear	
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anxiolytic	effects	are	induced	following	administration	
of the Sc. st. extract	in	the	medium	doses	used.	Smaller	
doses	of	the	extract	provided	only	insignificant	effects.	
The	highest	dose	(220	mg/kg)	exerted	weaker	effects	
on	the	OAT	and	OAE;	a	trend	toward	some	suppression	
of	LMA	was	observed	in	this	group.
Effects of i.c.v. Injections of the GABA
A
 Receptor 
Agonist and Antagonist on Anxiety Behavior in the 
EPM Test. Left	segments	of	the	panels	in	Fig.	2	illus­
trate	 the	 effects	of	 i.c.v.	 injections	of	different	doses	
of	muscimol.	A	one­way	ANOVA	and	post hoc	analy­
sis	 revealed	 that	 the	 effect	 of	muscimol	was	 signifi­
cant	 at	 the	 dose	 of	 1	µg/rat.	Muscimol	 increased	 the	
OAT	(F
(3,	28)
	=	5.69,	P <	0.005)	and	OAE	(F
(3,	28)
	=	3.31,	
P <	0.04),	but	 induced	no	significant	change	in	LMA	
(F
(3,	28)
	=	0.31,	P >	0.05).	These	data	indicate	that	clear	
anxiolytic	effects	were	induced	following	i.c.v.	admin­
istrations	 of	 the	 GABAA receptor	 agonist;	 the	 doses	 
of	 1.0	mg	 and,	 to	 a	 lesser,	 0.75	mg	were	 found	 to	 be	 
effective.	
However,	 rats	 i.c.v.	 infused	with	bicuculline	 (right	
segments	 of	 the	 panels	 in	 Fig.	 2)	 showed	 significant	
decreases	 in	 the	OAT	 (F
(3,	 28)
	 =	 6.93,	P <	 0.002)	 and	
OAE	(F
(3,	28)
	=	6.91,	P <	0.002)	at	the	dose	of	2	µg/rat.	 
The LMA	 changed	 insignificantly	 (F
(3,	 28)
	 =	 0.53,	 
P >	 0.05).	 Thus,	 certain	 anxiogenic	 responses	 were	
observed	following	injections	of	the	GABAA	receptor	
antagonist	 in	 all	 doses	 used,	 but	 such	 effects	 were	
especially	obvious	at	the	2.0	mg	dose.
Effects of the Sc. st. Extract alone or in Combi-
nation with i.c.v. Injections of Muscimol or 
Bicuculline on Anxiety Behavior. Figure	3	illustrates	
the	 effects	 of	 oral	 administration	 of	 effective	 doses	
of the Sc. st.	 extract	 or	 of	 vehicle	 consecutively	 for	
12	days	alone	or	in	combination	with	i.c.v.	injections	
of	 muscimol	 (1	 µg/rat)	 or	 bicuculline	 (1	 µg/rat)	
on	 anxiety­related	 behavior	 in	 the	 EPM	 test.	 In	 the	
GABAA	 agonist­treated	 groups,	 one­way	 ANOVA	
revealed	 that	 muscimol	 significantly	 increased	 the	
OAT	and	OAE	at	the	Sc. st.	extract	dose	of	160	mg/kg,	 
indicating	lower	levels	of	anxiety­related	behavior	in	
the Sc. st.+muscimol	 group	 in	 comparison	 with	 the	
water+muscimol	 (OAT:	F
(2,	21)
	=	7.49,	P <	0.005,	 and	
OAE:	F
(2,	21)
	=	4.25,	P <	0.03)	or	water+saline	 (OAT:	
F
(3, 28)
	 =	 21.43,	P <	 0.001,	 and	 OAE:	 F
(3,	 28)
	 =	 12.08,	 
P <	0.001)	control	groups.	Bicuculline	i.c.v.	injections	
noticeably	 decreased	 the	 OAT	 and,	 to	 a	 somewhat	
lesser	 extent,	 OAE,	 as	 compared	 with	 the	 control	
indices.	In	addition,	in	the	GABAA	antagonist­treated	
F i g. 2.	Effects	of	intracerebroventricular	injections	of	the	GABAA 
receptor	agonist	or	antagonist	on	rat	behavior	in	the	elevated	plus­
maze	 test.	Control	 rats	were	 treated	with	 saline	 (1	ml/rat,	Contr.),	
different	doses	of	muscimol	(0.5,	0.75,	and	1.0	µg/rat),	or	bicuculline	
(0.5,	1.0,	and	2.0	µg/rat)	5	min	before	the	EPM	test.	A­C)	Open­arm	
time,	%	(A),	open­arm	entries,	%	(B),	and	locomotor	activity	(C).	
*P < 0.05,	**P <	0.01,	and	***P <	0.001,	compared	to	the	control	
group.	Other	designations	are	similar	to	those	in	Fig.	1.
Р и с. 2.	Впливи	внутрішньошлуночкових	уведень	агоніста	та	
антагоніста	ГАМКA­рецепторів	на	поведінку	щурів	у	піднятому	
лабіринті.	
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groups,	one­way	ANOVA	revealed	that	bicuculline	did	
not	 alter	 the	OAT	 (F
(2,	21)
	 =	1.47,	P >	0.05)	 and	OAE	 
(F
(2,	 21)
	 =	 1.43,	 P >	 0.05)	 at	 all	 doses	 of	 Sc. st. in 
comparison	 with	 the	 water+muscimol	 control	 group.	
At	 the	same	time,	bicuculline	significantly	decreased	
the	former	index,	OAT	(F
(3,	28)
	=	5.96,	P <	0.004)	and,	
somewhat	 but	 insignificantly,	 OAE	 (F
(3,	 28)
	 =	 1.71,	 
P >	0.05)	at	all	doses	of	Sc. st.	in	comparison	with	the	
water+saline	 control	 group.	 No	 significant	 changes	
were	 observed	 in	 the	 LMA	 in	 all	 groups.	 Thus,	
bicuculline	 nearly	 completely	 eliminated	 anxiety­
suppressing	 effects	 of	 the	Sc. st. extract	 in	 the	 EPM 
test.
Two­way	 analyses	 revealed	 that	 there	 were	 no	
significant	 interactions	between	most	 effective	doses	
of Sc. st.	 (Factor	A)	and	muscimol	 (Factor	B)	on	 the	
OAT	 [Factor	 A:	 F
(2,	 42)
 =	 15.17, P < 0.001; Factor	
B: F
(1,	 42)
 =	 42.62, P < 0.001,	 and	 Factor	 (A	 ×	 B): 
F
(2,	42)
 =	0.4, P >	0.05],	OAE	[Factor	A: F
(2,	42)
 =	11.99,	 
P < 0.001, Factor	 B: F
(1,	 42)
 =	 11.24, P < 0.003,	 and	
Factor	 (A	 ×	 B): F
(2,	 42)
 =	 1.27, P >	 0.05],	 and	 LMA	
[Factor	A:	F
(2, 42)
 = 1.39, P >	0.05,	Factor	B:	F
(1,	42)
 = 
=	 1.6, P >	 0.05,	 and	 Factor	 (A	 ×	 B): F
(2,	 42)
 =	 0.45, 
P >	0.05].	
However,	two­way	analyses	revealed	that	significant	
interactions	 were	 observed	 between	 most	 effective	
doses	of	Sc. st.	(Factor	A)	and	bicuculline	(Factor	B)	
on	the	OAT	[Factor	A: F
(2,	42)
 =	7.92, P < 0.002,	Factor	
B:	 F
(1,	 42)
 =	 90.63, P < 0.001,	 and	 Factor	 (A	 ×	 B):	 
F
(2,	42)
 =	4.48, P < 0.02]	and	OAE	[Factor	A: F
(2,	42)
 = 
=	 6.58, P < 0.004,	 Factor	 B: F
(1,	 42)
 =	 38.44, 
P < 0.001,	and	Factor	(A	×	B):	F
(2,	42)
 =	4.45, P < 0.02].	No	
significant	interaction	was	found	with	respect	to	LMA	
[Factor	A: F
(2,	42)
 =	0.35, P >	0.05, Factor	B: F
(1,	42)
 =	0.14, 
P >	0.05,	and	Factor	(A	×	B): F
(2,	42)
 =	0.37, P >	0.05].
Effects of the Sc. st. Extract on Depression 
Behavior in the FST. Figure	 4A	 shows	 the	 effects	
of	oral	administration	of	different	doses	of	the	Sc. st. 
extract	or	vehicle	consecutively	for	12	days.	One­way	
ANOVA	and	post hoc	analysis	revealed	that	the	effects	
of Sc. st.	 were	 significant	 at	 the	 doses	 of	 100	 and	 
160	mg/kg.	This	 extract	 decreased	 the	 total	 duration	
of	immobility	segments (F
(5,	42)
 =	5.73, P < 0.001).	The	
results	 indicate	 that	 some	 antidepressant­like	 effects	
are	 observed	 following	 administration	 of	 the	 Sc. st. 
extract.
Effects of i.c.v. Injections of the GABA
A
 Receptor 
Agonist and Antagonist on Depression Behavior. 
Figure	4B	(left	part	of	the	panel)	illustrates	the	effects	
of	 i.c.v.	 injections	 of	 different	 doses	 of	 muscimol.	
One­way	ANOVA	and	post hoc	analysis	revealed	that	
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F i g. 3.	 Effects	 of	 an	 extract	 from	Scrophularia striata	 (Sc. st.)	
alone	 or	 in	 combination	 with	 intracerebroventricular	 (i.c.v.)	
injections	of	muscimol	or	 bicuculline	on	 anxiety	behavior	of	 rats	
in	 the	 elevated	 plus­maze	 test.	 Animals	 were	 treated	 with	 oral	
administration	of	the	effective	doses	of	the	Sc. st.	extract	or	vehicle	
consecutively	for	12	days;	then,	the	rats	received	i.c.v.	injections	of	
saline	(1	ml/rat),	muscimol	(1	µg/rat),	or	bicuculline	(1	mg/rat)	60	
min	after	the	last	treatment	with	the	extract	and	5	min	before	testing.	
Each	 bar	 represents	mean	 ±	 s.e.m.	 (n	 =	 8)	 of	 open­arm	 time,	%	
(A),	open­arm	entries,	%	(B),	or	locomotor	activity	(C).	Significant	
differences:	*P <	0.05, **P <	0.01,	and ***P <	0.001, compared	to	
the	control	(Contr.)	group;	+P <	0.05 and ++P <	0.01,	compared	to	
the	water+muscimol	control	group.
Р и с. 3. Впливи	 екстракту	 Scrophularia striata,	 введеного	
ізольовано	 або	 в	 комбінаціях	 із	 внутрішньошлуночковими	
ін’єкціями	мусцимолу	або	бікукуліну,	на	показники	тривожності	
щурів	при	тестуванні	в	піднятому	лабіринті.
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the	 effect	 of	 muscimol	 was	 significant	 at	 the	 dose	
of	 1	 µg/rat.	 Muscimol	 decreased	 the	 total	 duration	
of	 immobility	 (F
(3,	 28)
 =	 5.92, P < 0.004)	 in	 the	
FST.	 The	 data	 show	 that	 i.c.v.	 administration	 of	 the	
GABAA receptor	agonist	 in	 sufficient	doses	exerts	 an	
antidepressive	effect	in	the	FST.	
However,	rats	i.c.v.	 infused	with	different	doses	of	
bicuculline	 significantly	 increased	 the	 total	 duration	
of	 immobility	 periods	 (F
(3,	 28)
 =	 6.04, P < 0.004)	 at	
the	 dose	 of	 2	 µg/rat.	 These	 observations	 show	 that	
depression	 manifestations	 intensified	 in	 the	 FST	
following	injection	of	the	GABAA	receptor	antagonist	
(Fig.	4B,	right	part	of	the	panel).
Figure	 4C	 illustrates	 the	 effects	 of	 oral	
administration	of	effective	doses	of	the	Sc. st.	extract	
or	 of	 vehicle	 consecutively	 for	 12	 days	 alone	 or	 in	
combination	 with	 i.c.v.	 injections	 of	 muscimol	 
(1	µg/rat)	or	bicuculline	(1	µg/rat)	on	the	depression­
related	parameter	 in	 the	FST.	 In	 the	GABAA	 agonist­
treated	 groups,	 one­way	 ANOVA	 revealed	 that	
muscimol	significantly	decreased	the	total	duration	of	
immobility	 at	 the	 Sc. st.	 dose	 of	 100	 mg/kg.	 Lower	
levels	of	depression	in	the	Sc. st.+muscimol	group	in	
comparison	with	 the	 water+muscimol	 (F
(2,	 21)
 =	 3.68, 
P < 0.04)	or	water+saline	(F
(3,	28)
 =	12.48, P < 0.001)	
control	 groups	 were	 observed.	 In	 addition,	 in	 the	
GABAA	 antagonist­treated	 groups,	 one­way	ANOVA	
revealed	that	bicuculline	did	not	alter	the	total	duration	
of	immobility	(F
(2,	21)
 =	0.75, P >	0.05)	at	all	doses	of	
Sc. st.	in	comparison	with	the	water+muscimol	control	
group	but	significantly	increased	the	total	duration	of	
immobility	(F
(3,	28)
 =	8.30, P < 0.001)	at	all	doses	of	the	
extract	 in	 comparison	 with	 the	 water+saline	 control	
group.	Again,	 no	 significant	 change	was	 observed	 in	
the	LMA	index.
Two­way	 analyses	 revealed	 that	 there	 were	 no	
significant	 interactions	between	most	 effective	doses	
of Sc. st.	 (Factor	A)	and	muscimol	 (Factor	B)	on	 the	
total	 duration	 of	 immobility	 [Factor	A: F
(2,	 42)
 =	 9.1, 
P < 0.002, Factor	 B: F
(1,	 42)
 =	 15.43, P < 0.001,	 and	
Factor	(A	×	B): F
(2,	42)
 =	1.05, P >	0.05].	These	analyses	
also	revealed	that	there	were	no	significant	interactions	
between	most	effective	doses	of	Sc. st.	(Factor	A)	and	
bicuculline	 (Factor	 B)	 on	 this	 parameter	 [Factor	 A: 
F
(2,	 42)
 =	 5.65, P < 0.008, Factor	 B: F
(1,	 42)
 =	 114.21, 
P < 0.001	and	Factor	(A	×	B):	F
(2,	42)
 =	0.17, P >	0.05]	
in	the	FST	test.
F i g. 4.	 Effects	 of	 an	 extract	 from	Scrophularia striata	 (Sc. st.)	
alone	 or	 in	 combination	 with	 intracerebroventricular	 (i.c.v.)	
injections	 of	 muscimol	 or	 bicuculline	 on	 depression	 behavior	 in	
the	forced	swimming	test.	A)	Oral	administration	of	different	doses	
of the S. s.	 extract	 or	 vehicle	 consecutively	 for	 12	days,	B)	 i.c.v.	
injections	of	the	GABAA	receptor	agonist	or	antagonist,	and	C)	oral	
administration	 of	 the	Sc. st.	 extract	 alone	 or	 in	 combination	with	
i.c.v.	 injections	 of	 muscimol	 or	 bicuculline.	 Results	 of	 statistical	
analysis	and	post-hoc	comparisons	are	described	 in	Results.	Each	
bar	represents	mean	±	s.e.m.	(n =	8)	of	total	duration	of	immobility.	
Significant	differences:	*P <	0.05, **P <	0.01,	and ***P <	0.001, 
compared	 to	 the	 control	 (Contr.)	 or	 saline	 group;	 +P <	 0.05, 
compared	to	the	water+muscimol	control	group.
Р и с. 4.	 Впливи	 екстракту	 Scrophularia striata,	 введеного	
ізольовано	 або	 в	 комбінаціях	 із	 внутрішньошлуночковими	
ін’єкціями	 мусцимолу	 або	 бікукуліну,	 на	 показники	
депресивності	щурів	у	тестах	вимушеного	плавання.
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DISCUSSION 
To	 our	 knowledge,	 this	 is	 the	 first	 report	 on	
pharmacological	effects	of	Sc. st.	on	neuropsychiatric	
indices	 in	 experimental	 animals.	 Our	 results	
demonstrated	that	administration	of	the	Sc. st.	extract	
decreases	 the	 levels	 of	 anxiety	 and	 depression­like	
behaviors	in	rats.	As	was	mentioned above,	a	recently	
published	study	conducted	by	Monsef­Esfahani	et	al.	
[12]	 showed	 the	 presence	 of	 a	 quercetin	 flavonoid	
among	 effective	 compounds	 of	 this	 plant.	 On	 the	
other	 hand,	 some	authors	 reported	 that	 quercetin	 can	
decrease	the	anxiety	and	depression	levels	[13,	14]	and	
also	demonstrated	a	relationship	between	the	quercetin	
effects	and	the	activity	of	neurotransmitter	systems	in	
the	CNS	[19­21].	Thus,	mental­related	behaviors	can	
be	 altered	 through	 indirect	 mechanisms.	 To	 explore	
this	 issue	 further,	 we	 investigated	 the	 interaction	
between	 the	 effects	 of	 Sc. st.	 and	 the	 GABA­ergic	
cerebral	 system.	 In	 this	 regard,	 i.c.v.	microinjections	
of	 muscimol	 decreased	 the	 levels	 of	 anxiety	 and	
depression,	 whereas	 administration	 of	 bicuculline	 in	
this	 brain	 site	 increased	 the	 levels	 of	 the	 respective	
disorders.	 The	 exact	 role	 of	 GABA­ergic	 networks	
in	various	 areas	of	 brain	 in	 the	 regulation	of	 anxiety	
and	 depression	 has	 not	 been	 clearly	 recognized.	Our	
data	agree	with	the	results	of	previous	studies,	which	
demonstrated	 that	 the	 GABA­ergic	 system	 plays	 an	
important	role	in	the	regulation	and	control	of	anxiety	
and	depression,	and	that	GABA­ergic	agents	or	drugs	
exert	powerful	anxiolytic	and	antidepressive	effects	in	
humans	and	animals	[9].	Moreover,	another	part	of	our	
study	 showed	 that	 co­administration	 of	 bicuculline	
with	 the	 Sc. st.	 extract	 decreased	 anxiolytic	 and	
antidepressant­like	 effects,	 while	 co­administration	
of	muscimol	with	this	extract	increased	the	respective	
effects	 relative	 to	 the	 control	 group.	 These	 findings	
demonstrate	 that	 the	 GABAA agonist	 can	 enhance	
anxiolytic	 and	 antidepressive	 influences	 of	 active	
components	 of	 Sc. st.,	 while	 the	 GABAA antagonist	
considerably	blocks	these	effects.
Furthermore,	 it	 is	well	 known	 that	 stress	 activates	
the	hypothalamic­pituitary­adrenal	(HPA)	axis	mostly	
via	 stimulation	 of	 corticotrophin­releasing	 factor	
(CRF)	 release	 from	 the	 hypothalamus.	 In	 the	 next	
step,	CRF	stimulates	secretion	of	adrenocorticotropin	
(ACTH)	 from	 the	 anterior	 pituitary	 and	 also	 that	 of	
the	 stress	 hormones,	 such	 as	 cortisol	 in	 humans	 and	
corticosterone	 in	 rodents	 [13].	 As	 a	 consequence,	
it	 should	 be	 emphasized	 that	 the	 CRF	 system	 is	
responsible	for	the	regulation	of	anxiety	and	depression­
related	 behaviors.	 In	 line	 with	 this,	 a	 recent	 report	
demonstrated	that	quercetin	attenuates	stress­induced	
behavioral	 effects.	 It	 also	 decreases	 CRF	 expression	
in	 the	 brain	 [13].	On	 the	 one	 hand,	 numerous	 recent	
studies	 described	 anti­inflammatory	 effects	 of	 the	 
Sc. st. extract in	rodents,	and	the	presence	of	quercetin	
flavonoid	in	this	plant	was	identified	[10,	12].	On	the	
other	hand,	several	studies	demonstrated	antioxidant,	
anti­inflammatory,	 neuroprotective,	 anxiolytic,	 and	
antidepressive	 effects	 of	 quercetin	 in	 experimental	
models	[13,	14].	Collectively,	it	 is	conceivable	in	the	
light	 of	 presented	 evidence	 that	 the	 effects	 of	Sc. st. 
could	 be	mostly	 related	 to	 the	 presence	 of	 quercetin	
among	the	constituents	of	this	plant.
Therefore,	our	experiments	showed	that	the	extract	
of Sc. st. effectively	 decreases	 the	 levels	 of	 anxiety	
and	 depression	 in	 rats.	 Although	 the	 mechanisms	
providing	 suppression	 of	 these	 disorders	 under	 the	
conditions	 tested	 are	 likely	 complex,	 the	 above	
evidences	 suggest	 that	 the	 GABA­ergic	 system	 may	
mediate,	to	a	conciderable	extent,	the	effects	of	the Sc. 
st.	extract.	More	studies	are	needed	to	investigate	more	
fully	these	pharmacological	effects	and	the	respective	
involvement	of	different	neurotransmitter	systems.
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Р	е	з	ю	м	е
Нещодавно	 в	 експериментах	 на	 гризунах	 були	 продемон­
стровані	 нейропротективні	 та	 протизапальні	 ефекти	 екс­
тракту	 ранника	 смугастого,	 Scrophularia striata	 Boiss	 (Sc. 
st.,	 Scrophulariaceae).	 Ми	 досліджували	 впливи	 екстракту	
Sc. st. на	аспекти	поведінки	щурів,	пов’язані	з	тривожністю	
та	 депресивністю,	 і	 намагалися	 з’ясувати	 механізми,	 від­
повідальні	за	реалізацію	цих	впливів.	Тестували	поведінку	
в	піднятому	лабіринті	(ПЛ)	 і	в	тесті	вимушеного	плавання	
(ТВП).	20,	50,	100,	160	або	220	мг/кг	сухої	речовини	спирто­
вого	екстракту	Sc. st.	уводилися	перорально	у	вигляді	вод­
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ного	розчину.	Ми	також	досліджували	взаємодію	екстракту	
Sc. st.	в	ефективних	дозах	і	ГАМК
А
­рецепторів	у	головному	
мозку.	Екстракт	у	дозах	100	та	160	мг/кг	забезпечував	віро­
гідне	 збільшення	 нормованих	 значень	 часу	 перебування	 у	
відкритій	гілці	ПЛ	і	числа	входів	до	неї	і	зменшував	трива­
лість	періоду	нерухомості	в	ТВП	порівняно	з	відповідними	
значеннями	 в	 контрольній	 групі;	 це	 свідчило,	 відповідно,	
про	 анксіолітичний	 та	 антидепресивний	 ефекти.	Внутріш­
ньошлуночкові	 введення	 агоніста	 ГАМКA­рецепторів	 мус­
цимолу	(0.5,	0.75	і	1	мкг	на	тварину)	посилювали	відповід­
ні	ефекти	Sc. st. Антагоніст	же	ГАМКA­рецепторів	бікукулін	
(0.5,	 1	 і	 2	мкг	на	щура)	блокував	ці	 ефекти.	Таким	чином,	
анксіолітичні	 та	 антидепресивні	 ефекти	 активних	 компо­
нентів	Sc. st.	можуть	опосередковуватися	модуляцією	стану	
ГАМК­ергічної	системи.	
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